Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778–89. https://doi.org/10.1002/ijc.33588

Article  CAS  Google Scholar 

Romito F, Goldzweig G, Cormio C, Hagedoorn M, Andersen BL. Informal caregiving for cancer patients. Cancer. 2013;119:2160–9. https://doi.org/10.1002/cncr.28057

Article  PubMed  Google Scholar 

Li F, Wu X, Zhou Q, Zhu DW. Clonal hematopoiesis of indeterminate potential (CHIP): a potential contributor to atherlosclerotic cardio/cerebro-vascular diseases? Genes Dis. 2018;5:75–76. https://doi.org/10.1016/j.gendis.2018.04.001

Article  CAS  PubMed  PubMed Central  Google Scholar 

WHO REPORT ON CANCER SETTING PRIORITIES, INVESTING WISELY AND PROVIDING CARE FOR ALL 2020 WHO report on cancer: setting priorities, investing wisely and providing care for all. 2020. http://apps.who.int/bookorders.

Nasir MU, Ghazal TM, Khan MA, Zubair M, Rahman A, Ahmed R, et al. Breast cancer prediction empowered with fine-tuning. Comput Intell Neurosci. 2022;2022:1–9. https://doi.org/10.1155/2022/5918686

Article  Google Scholar 

Podo F, Buydens LMC, Degani H, Hilhorst R, Klipp E, Gribbestad IS, et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 2010;4:209–29. https://doi.org/10.1016/j.molonc.2010.04.006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel RV, Mistry BM, Gujarati AV, Patel AB, Patel DK. Epidermal growth factor receptor inhibiting 4‐aminoquinazolines as promising anticancer agents: a patent review (2000‐Present). ChemistrySelect. 2023;8:1–28. https://doi.org/10.1002/slct.202301053

Article  CAS  Google Scholar 

Guo Y-C, Zhang M, Wang F-X, Pei G-C, Sun F, Zhang Y, et al. Macrophages regulate unilateral ureteral obstruction-induced renal lymphangiogenesis through C-C motif chemokine receptor 2–dependent phosphatidylinositol 3-kinase-AKT–mechanistic target of rapamycin signaling and hypoxia-inducible factor-1α/vascular endothelial growth factor-C expression. Am J Pathol. 2017;187:1736–49. https://doi.org/10.1016/j.ajpath.2017.04.007

Article  CAS  PubMed  Google Scholar 

Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797–803. https://doi.org/10.1097/01.cad.0000173476.67239.3b

Article  CAS  PubMed  Google Scholar 

Hawkins PT, Stephens LR. PI3K signalling in inflammation. Biochim Biophys Acta Mol Cell Biol Lipids. 2015;1851:882–97. https://doi.org/10.1016/j.bbalip.2014.12.006

Article  CAS  Google Scholar 

Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol. 2005;17:150–7. https://doi.org/10.1016/j.ceb.2005.02.010

Article  CAS  PubMed  Google Scholar 

Kim YC, Guan K-L. mTOR: a pharmacologic target for autophagy regulation. J Clin Investig. 2015;125:25–32. https://doi.org/10.1172/JCI73939

Article  PubMed  PubMed Central  Google Scholar 

van Krieken JHJM, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453:417–31. https://doi.org/10.1007/s00428-008-0665-y

Article  CAS  PubMed  Google Scholar 

Spicer JF, Rudman SM. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol. 2010;5:245–55. https://doi.org/10.1007/s11523-010-0140-y

Article  PubMed  Google Scholar 

Sun X, Xu S, Yang Z, Zheng P, Zhu W. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present). Expert Opin Ther Pat. 2021;31:223–38. https://doi.org/10.1080/13543776.2021.1860210

Article  CAS  PubMed  Google Scholar 

Bauer A, Brönstrup M. Industrial natural product chemistry for drug discovery and development. Nat Prod Rep. 2014;31:35–60. https://doi.org/10.1039/C3NP70058E

Article  CAS  PubMed  Google Scholar 

Shukla A, Maiti P. Nanomedicine and versatile therapies for cancer treatment. MedComm. 2022;3:1–31. https://doi.org/10.1002/mco2.163

Article  CAS  Google Scholar 

Kushwaha N, Sharma CS. The chemistry of triazine isomers: structures, reactions, synthesis and applications. Mini Rev Med Chem. 2021;20:2104–22. https://doi.org/10.2174/1389557520666200729160720

Article  CAS  Google Scholar 

Sahin Z, Biltekin SN, Ozansoy M, Hemiş B, Ozansoy MB, Yurttaş L, et al. Synthesis and in vitro antitumor activities of novel thioamide substituted piperazinyl‐1,2, <scp>4‐triazines</scp>. J Heterocycl Chem. 2022;59:1333–40. https://doi.org/10.1002/jhet.4470

Article  CAS  Google Scholar 

Zhu X-Q, Zhang M-T, Yu A, Wang C-H, Cheng J-P. Hydride, hydrogen atom, proton, and electron transfer driving forces of various five-membered heterocyclic organic hydrides and their reaction intermediates in acetonitrile. J Am Chem Soc. 2008;130:2501–16. https://doi.org/10.1021/ja075523m

Article  CAS  PubMed  Google Scholar 

Guo H, Diao Q-P. 1,3,5-Triazine-azole hybrids and their anticancer activity. Curr Top Med Chem. 2020;20:1481–92. https://doi.org/10.2174/1568026620666200310122741

Article  CAS  PubMed  Google Scholar 

Kumari S, Singh A. Various techniques for one-pot synthesis of 1,3,5-triazine (s-Triazine) derivatives: a review. Mini Rev Org Chem. 2022;19:52–65. https://doi.org/10.2174/1570193X18666210225115511

Article  CAS  Google Scholar 

Leung EY, Kim JE, Askarian-Amiri M, Joseph WR, McKeage MJ, Baguley BC. Hormone resistance in two MCF-7 breast cancer cell lines is associated with reduced mtor signaling, decreased glycolysis, and increased sensitivity to cytotoxic drugs. Front Oncol. 2014;4:1–9. https://doi.org/10.3389/fonc.2014.00221

Article  Google Scholar 

Xiao M, Zhu M, Wu S, Ma L, Qi L, Ha S, et al. Novel 6-amino-1,3,5-triazine derivatives as potent BTK inhibitors: structure-activity relationship (SAR) analysis and preliminary mechanism investigation. Bioorg Chem. 2023;130:106263 https://doi.org/10.1016/j.bioorg.2022.106263

Article  CAS  PubMed  Google Scholar 

Srivastava JK, Pillai GG, Bhat HR, Verma A, Singh UP. Design and discovery of novel monastrol-1,3,5-triazines as potent anti-breast cancer agent via attenuating Epidermal Growth Factor Receptor tyrosine kinase. Sci Rep. 2017;7:5851 https://doi.org/10.1038/s41598-017-05934-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yan W, Zhao Y, He J. Anti-breast cancer activity of selected 1,3,5-triazines via modulation of EGFR-TK. Mol Med Rep. 2018;18:4175–84. https://doi.org/10.3892/mmr.2018.9426

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhat HR, Masih A, Shakya A, Ghosh SK, Singh UP. Design, synthesis, anticancer, antibacterial, and antifungal evaluation of 4‐aminoquinoline‐1,3,5‐triazine derivatives. J Heterocycl Chem. 2020;57:390–9. https://doi.org/10.1002/jhet.3791

Article  CAS  Google Scholar 

Pathak P, Rimac H, Grishina M, Verma A, Potemkin V. Hybrid quinazoline 1,3,5‐triazines as epidermal growth factor receptor (EGFR) inhibitors with anticancer activity: design, synthesis, and computational study. ChemMedChem. 2021;16:822–38. https://doi.org/10.1002/cmdc.202000646

Article  CAS  PubMed  Google Scholar 

Moreno LM, Quiroga J, Abonia R, Lauria A, Martorana A, Insuasty H, et al. Synthesis, biological evaluation, and in silico studies of novel chalcone- and pyrazoline-based 1,3,5-triazines as potential anticancer agents. RSC Adv. 2020;10:34114–29. https://doi.org/10.1039/D0RA06799G

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raghu MS, Pradeep Kumar CB, Prashanth MK, Yogesh Kumar K, Prathibha BS, Kanthimathi G, et al. Novel 1,3,5-triazine-based pyrazole derivatives as potential antitumor agents and EFGR kinase inhibitors: synthesis, cytotoxicity, DNA binding, molecular docking and DFT studies. N. J Chem. 2021;45:13909–24. https://doi.org/10.1039/D1NJ02419A

Article  CAS  Google Scholar 

Hashem HE, Amr AE-GE, Nossier ES, Anwar MM, Azmy EM. New benzimidazole-, 1,2,4-triazole-, and 1,3,5-triazine-based derivatives as potential EGFR WT and EGFR T790M inhibitors: microwave-assisted synthesis, anticancer evaluation, and molecular docking study. ACS Omega. 2022;7:7155–71. https://doi.org/10.1021/acsomega.1c06836

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shawish I, Nafie MS, Barakat A, Aldalbahi A, Al-Rasheed HH, Ali M, et al. Pyrazolyl-s-triazine with indole motif as a novel of epidermal growth factor receptor/cyclin-dependent kinase 2 dual inhibitors. Front Chem. 2022;10:1–19. https://doi.org/10.3389/fchem.2022.1078163

Article  CAS  Google Scholar 

Shawish I, Barakat A, Aldalbahi A, Malebari AM, Nafie MS, Bekhit AA, et al. Synthesis and antiproliferative activity of a new series of mono- and bis(dimethylpyrazolyl)- s -triazine derivatives targeting EGFR/PI3K/AKT/mTOR signaling cascades. ACS Omega. 2022;7:24858–70. https://doi.org/10.1021/acsomega.2c03079

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shawish I, Barakat A, Aldalbahi A, Alshaer W, Daoud F, Alqudah DA, et al. Acetic acid mediated for one-pot synthesis of novel pyrazolyl s-triazine derivatives for the targeted therapy of triple-negative breast tumor cells (MDA-MB-231) via EGFR/PI3K/AKT/mTOR signaling cascades. Pharmaceutics. 2022;14:1558 https://doi.org/10.3390/pharmaceutics14081558

Article  CAS  PubMed  PubMed Central